IMA401-101 – Treatment of patients with solid tumors with IMA401 TCER®, a bispecific T-cell receptor (Phase I trial); alone or in combination with checkpoint inhibitor

2023-506854-19-00 Protocol IMA401-101 Human pharmacology (Phase I) - First administration to humans Ongoing, recruitment ended

Start 19 May 2022 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 21 sites · Protocol IMA401-101

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruitment ended
Participants planned 95
Countries 1
Sites 21

Solid Tumors

Key facts

Sponsor
Immatics Biotechnologies GmbH
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
19 May 2022 → ongoing
Decision date (initial)
2023-09-28
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-506854-19-00
EudraCT number
2021-004326-30
ClinicalTrials.gov
NCT05359445

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Solid Tumors

VersionLevelCodeTermSystem organ class
21.1 LLT 10065252 Solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Immatics Biotechnologies GmbH

Sponsor organisation
Immatics Biotechnologies GmbH
Address
Paul-Ehrlich-Strasse 15, Waldhaeuser Waldhaeuser
City
Tuebingen
Postcode
72076
Country
Germany

Scientific contact point

Organisation
Immatics Biotechnologies GmbH
Contact name
Clinical Development

Public contact point

Organisation
Immatics Biotechnologies GmbH
Contact name
Clinical Development

Locations

1 EU/EEA country · 21 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruitment ended 95 21
Rest of world 0

Investigational sites

Germany

21 sites · Ongoing, recruitment ended
Universitaetsklinikum Wuerzburg AöR
Interdisziplinäres Studienzentrum mit ECTU, Straubmuehlweg 2a, Grombuehl, Wuerzburg
Charite Universitaetsmedizin Berlin KöR
Klinik für Hämatologie und Onkologie, Hindenburgdamm 30, Lichterfelde, Berlin
Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR
NCT/UCC Early Clinical Trial Unit, Fetscherstrasse 74, Johannstadt-Nord, Dresden
Marien Hospital Duesseldorf GmbH
Klinik für Onkologie / Hämatologie und Palliativmedizin, Rochusstrasse 2, Pempelfort, Duesseldorf
Goethe University Frankfurt
Medizinische Klinik II, Theodor-Stern-Kai 7, 60590, Frankfurt Am Main
Medical Center - University Of Freiburg
Klinik für Innere Medizin I, Hugstetter Strasse 55, Stuehlinger, Freiburg Im Breisgau
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
III. Medizinische Klinik, Langenbeckstrasse 1, Oberstadt, Mainz
Klinikum rechts der Isar der TU Muenchen AöR
Klinik und Poliklinik für Innere Medizin III, Ismaninger Strasse 22, Au-Haidhausen, Munich
Universitaetsklinikum Bonn AöR
Medizinische Klinik III, Venusberg-Campus 1, Venusberg, Bonn
Universitaetsklinikum Regensburg AöR
Klinik für Innere Medizin 3, Franz-Josef-Strauss-Allee 11, Grass-Oberisling, Regensburg
Universitaetsklinikum Tuebingen AöR
Comprehensive Cancer Center Tübingen, Otfried-Mueller-Strasse 10, Nordstadt, Tuebingen
Universitaetsklinikum Muenster AöR
Medizinische Klinik A, Albert-Schweitzer-Campus 1, Sentrup, Muenster
Thoraxklinik Heidelberg gGmbH
Studienzentrum Thoraxonkologie, Roentgenstrasse 1, Rohrbach, Heidelberg
Universitaet Leipzig
Universitäres Krebszentrum Leipzig (UCCL), Liebigstrasse 22, Zentrum-Suedost, Leipzig
Klinikum Nuernberg
Klinik für Innere Medizin 5, Abteilung Onkologie/Hämatologie, Prof.-Ernst-Nathan-Strasse 1, St. Johannis, Nuremberg
Universitaetsklinikum Erlangen AöR
Interdisciplinary Clinical Trial Unit with ECTU, Ulmenweg 18, Innenstadt, Erlangen
Universitaetsklinikum Ulm AöR
ECTU-Early Clinical Trials Unit Universitätsklinikum Ulm Comprehensive Cancer Center Ulm_CCCU, Albert-Einstein-Allee 23, Eselsberg, Ulm
Klinikum Chemnitz gGmbH
Klinik für Innere Medizin III, Flemmingstrasse 2, Altendorf, Chemnitz
Universitaetsklinikum Heidelberg AöR
Nationales Zentrum für Tumorkrankheiten, Im Neuenheimer Feld 460, Neuenheim, Heidelberg
Medizinische Hochschule Hannover
Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Carl-Neuberg-Strasse 1, Gross Buchholz, Hanover
Universitaetsklinikum Schleswig-Holstein
Campus Kiel, Medizinische Klinik II Hämatologie und Onkologie, Karl-Lennert Tumorzentrum, Arnold-Heller-Strasse 3, Brunswik, Kiel

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2022-05-19 2022-05-19 2026-01-05

Application history

7 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-09-01 Germany Acceptable
2023-09-22
2023-09-28
2 SUBSTANTIAL MODIFICATION SM-1 2023-12-07 Germany Acceptable
2024-01-19
2024-02-02
3 SUBSTANTIAL MODIFICATION SM-2 2024-02-28 Germany Acceptable
2024-04-12
2024-04-15
4 SUBSTANTIAL MODIFICATION SM-3 2024-10-04 Germany Acceptable with conditions
2024-12-03
2024-12-04
5 SUBSTANTIAL MODIFICATION SM-4 2025-04-22 Germany Acceptable
2025-06-25
2025-06-30
6 SUBSTANTIAL MODIFICATION SM-5 2025-07-14 Germany Acceptable 2025-08-19
7 SUBSTANTIAL MODIFICATION SM-6 2026-02-20 Germany Acceptable 2026-03-10